Evidence map›Paper›PMID 42129334›Full record

ArticleScientific reports2026

MTAP loss in gastrointestinal cancers is associated with CDKN2A deletion, poor prognosis in gastric carcinoma, and potential relevance for PRMT5-targeted therapy.

Su Ir Lyu, Karl Knipper, Caroline Fretter, Eleni Tzitzili, Adrian Georg Simon, Hakan Alakus, Aylin Pamuk, Christiane J Bruns, Thomas Schmidt, Felix C Popp and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Su Ir LyuFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany. su.lyu@uk-koeln.de.
Karl KnipperFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Caroline FretterFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Eleni TzitziliFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Adrian Georg SimonFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.
Hakan AlakusFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Aylin PamukFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Christiane J BrunsFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Thomas SchmidtFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Felix C PoppFaculty of Medicine and University Hospital of Cologne, Department of General, Visceral, Thoracic and Transplantation Surgery, University of Cologne, Cologne, Germany.
Alexander QuaasFaculty of Medicine and University Hospital of Cologne, Institute of Pathology, University of Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal cancers account for a substantial share of global cancer burden. We assessed the significance of MTAP loss across 1545 resected tumors (cholangiocarcinoma, esophageal and gastric adenocarcinoma, pancreatic ductal adenocarcinoma). MTAP protein was evaluated by immunohistochemistry compared with CDKN2A status by fluorescence in situ hybridization and with overall survival. Immunohistochemical MTAP loss consistently co-occurred with homozygous CDKN2A deletion and was present in 25.5% of cholangiocarcinomas, 9.3% of esophageal adenocarcinomas, 10.3% of gastric carcinomas, and 30.2% of pancreatic adenocarcinomas. In gastric carcinomas, MTAP loss was associated with worse survival (p = 0.024), particularly in those who underwent primary surgery (p = 0.008). MTAP loss proved to be an independent factor for worse overall survival in patients with gastric adenocarcinoma. 10% of esophageal adenocarcinomas showed intratumoral heterogeneity, but we did not see intertumoral heterogeneity between the primary tumor and corresponding lymph node metastases. These data indicate that a considerable subset of gastrointestinal cancers exhibits MTAP loss, highlight prognostic relevance in gastric carcinoma, and delineate a potentially actionable subgroup for PRMT5 inhibitor therapy.

Indexed as

Cyclin-Dependent Kinase Inhibitor p16Gastrointestinal NeoplasmsGene DeletionProtein-Arginine N-MethyltransferasesPurine-Nucleoside PhosphorylaseStomach NeoplasmsAgedFemaleHumansMaleMiddle AgedPrognosis5'-methylthioadenosine phosphorylaseCDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p16PRMT5 protein, humanProtein-Arginine N-MethyltransferasesPurine-Nucleoside PhosphorylaseEsophageal cancerGastric cancerMTAP-lossPancreatic cancerPRMT5-inhibitor

Identifiers

PMID42129334
PMCPMC13172544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.